[1]
|
Sumida, Y. and Yoneda, M. (2018) Current and Future Pharmacological Therapies for NAFLD/NASH. Journal of Gastroenterology, 53, 362-376. https://doi.org/10.1007/s00535-017-1415-1
|
[2]
|
Angelico, F., Del Ben, M., Conti, R., Francioso, S., Feole, K., Maccioni, D., Antonini, T.M. and Alessandri, C. (2003) Non-Alcoholic Fatty Liver Syndrome: A Hepatic Consequence of Common Metabolic Diseases. Journal of Gastroenterology and Hepatology, 18, 588-594. https://doi.org/10.1046/j.1440-1746.2003.02958.x
|
[3]
|
Del Ben, M., Polimeni, L., Baratta, F., Pastori, D. and Angelico, F. (2017) The Role of Nutraceuticals for the Treatment of Non-Alcoholic Fatty Liver Disease. British Journal of Clinical Pharmacology, 83, 88-95.
https://doi.org/10.1111/bcp.12899
|
[4]
|
Younossi, Z.M. (2019) Non-Alcoholic Fatty Liver Disease—A Global Public Health Perspective. Journal of Hepatology, 70, 531-544. https://doi.org/10.1016/j.jhep.2018.10.033
|
[5]
|
王宇, 郑锦锋. 非酒精性脂肪肝营养干预的研究进展[J]. 医学研究生学报, 2014, 27(1): 99-101.
|
[6]
|
Wei, J., Lei, G.H., Fu, L., Zeng, C., Yang, T. and Peng, S.F. (2016) Association between Dietary Vitamin C Intake and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study among Middle-Aged and Older Adults. PLoS ONE, 11, e0147985. https://doi.org/10.1371/journal.pone.0147985
|
[7]
|
Ivancovsky-Wajcman, D., Fliss-Isakov, N., Salomone, F., Webb, M., Shibolet, O., Kariv, R. and Zelber-Sagi, S. (2019) Dietary Vitamin E and C Intake Is Inversely Associated with the Severity of Nonalcoholic Fatty Liver Disease. Digestive and Liver Disease, 51, 1698-1705. https://doi.org/10.1016/j.dld.2019.06.005
|
[8]
|
El Hadi, H., Vettor, R. and Rossato, M. (2018) Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth? Antioxidants (Basel), 7, 12. https://doi.org/10.3390/antiox7010012
|
[9]
|
赖荣陶, 陈成伟. 维生素E与慢性肝病的治疗[J]. 肝脏, 2007, 12(6): 508-509.
|
[10]
|
Buettner, G.R. (1993) The Pecking Order of Free Radicals and Antioxidants: Lipid Peroxidation, Alpha-Tocopherol, and Ascorbate. Archives of Biochemistry and Biophysics, 300, 535-543. https://doi.org/10.1006/abbi.1993.1074
|
[11]
|
Ipsen, D.H., Tveden-Nyborg, P. and Lykkesfeldt, J. (2014) Does Vitamin C Deficiency Promote Fatty Liver Disease Development? Nutrients, 6, 5473-5499. https://doi.org/10.3390/nu6125473
|
[12]
|
Ashraf, N.U. and Sheikh, T.A. (2015) Endoplasmic Reticulum Stress and Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease. Free Radical Research, 49, 1405-1418.
https://doi.org/10.3109/10715762.2015.1078461
|
[13]
|
Ooi, G.J., Meikle, P.J., Huynh, K., Earnest, A., Roberts, S.K., Kemp, W., Parker, B.L., Brown, W., Burton, P. and Watt, M.J. (2021) Hepatic Lipidomic Remodeling in Severe Obesity Manifests with Steatosis and Does Not Evolve with Non-Alcoholic Steatohepatitis. Journal of Hepatology, 75, 524-535. https://doi.org/10.1016/j.jhep.2021.04.013
|
[14]
|
Sanyal, A.J., Chalasani, N., Kowdley, K.V., McCullough, A., Diehl, A.M., Bass, N.M., Neuschwander-Tetri, B.A., Lavine, J.E., Tonascia, J., Unalp, A., et al. (2010) Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. The New England Journal of Medicine, 362, 1675-1685. https://doi.org/10.1056/NEJMoa0907929
|
[15]
|
Manne, V., Handa, P. and Kowdley, K.V. (2018) Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Clinical Liver Disease, 22, 23-37. https://doi.org/10.1016/j.cld.2017.08.007
|
[16]
|
Harrison, S.A., Torgerson, S., Hayashi, P., Ward, J. and Schenker, S. (2003) Vitamin E and Vitamin C Treatment Improves Fibrosis in Patients with Nonalcoholic Steatohepatitis. American Journal of Gastroenterology, 98, 2485-2490.
https://doi.org/10.1111/j.1572-0241.2003.08699.x
|
[17]
|
Kawanaka, M., Nishino, K., Nakamura, J., Suehiro, M., Goto, D., Urata, N., Oka, T., Kawamoto, H., Nakamura, H., Yodoi, J., et al. (2013) Treatment of Nonalcoholic Steatohepatitis with Vitamins E and C: A Pilot Study. Hepatic Medicine: Evidence and Research, 5, 11-16. https://doi.org/10.2147/HMER.S41258
|
[18]
|
Schuster, S., Cabrera, D., Arrese, M. and Feldstein, A.E. (2018) Triggering and Resolution of Inflammation in NASH. Nature Reviews Gastroenterology & Hepatology, 15, 349-364. https://doi.org/10.1038/s41575-018-0009-6
|
[19]
|
Qi, A.Q., Li, Y., Liu, Q., Si, J.Z., Tang, X.M., Zhang, Z.Q., Qi, Q.D. and Chen, W.B. (2015) Thioredoxin Is a Novel Diagnostic and Prognostic Marker in Patients with Ischemic Stroke. Free Radical Biology & Medicine, 80, 129-135.
https://doi.org/10.1016/j.freeradbiomed.2014.12.021
|
[20]
|
Eslam, M., Newsome, P.N., Sarin, S.K., Anstee, Q.M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun, W.V., Dufour, J.F., Schattenberg, J.M., et al. (2020) A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement. Journal of Hepatology, 73, 202-209.
https://doi.org/10.1016/j.jhep.2020.03.039
|